<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03545997</url>
  </required_header>
  <id_info>
    <org_study_id>38RC17.107</org_study_id>
    <nct_id>NCT03545997</nct_id>
  </id_info>
  <brief_title>Montelukast for Patients With Obstructive Sleep Apnea Syndrome</brief_title>
  <acronym>MONTSAS</acronym>
  <official_title>Impact of Blocked Cysteinyl Leukotriene Pathway on Endothelial Function in Patients With Obstructive Sleep Apnea Syndrome: Multicenter Randomized Placebo Controlled Crossover Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Act For Chronic Diseases</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Direction Générale de l'Offre de Soins</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares the effect of Montelukast vs Placebo on Flow Mediated Dilatation of the&#xD;
      Brachial Artery (FMD) in patients with obstructive sleep apnea syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obstructive Sleep Apnea Syndrome (OSAS) induces low-grade systemic and vascular inflammation,&#xD;
      including activation of the leukotriene pathway.&#xD;
&#xD;
      In apneic patients, the urinary excretion of LTE4, a systemic marker of CysLT pathway&#xD;
      activation, is increased in relation to the severity of OSAS and it's an independent&#xD;
      predictor of cardiovascular risk event occurring at 10 years.&#xD;
&#xD;
      Montelukast is a CysLT1 receptor antagonist. By blocking CysLT1 receptors, montelukast&#xD;
      prevents vasoconstriction, proliferation and migration of smooth muscle cells, adhesion&#xD;
      molecule expression, and leukocyte recruitment induced by CysLTs.Montelukast may improve&#xD;
      endothelial function and reduce vascular remodeling in apneic patients.&#xD;
&#xD;
      A pharmacological blockade of CysLT pathway would be an interesting therapeutic strategy to&#xD;
      limit the cardiovascular consequences of OSAS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    lack of recruitment&#xD;
  </why_stopped>
  <start_date type="Actual">November 29, 2019</start_date>
  <completion_date type="Actual">March 20, 2020</completion_date>
  <primary_completion_date type="Actual">March 20, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>It's a prospective, randomized, comparative vs placebo, double blind, multicenter, national study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Montelukast will be crushed and coated in a capsule, Mannitol is into a capsule too.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in FMD of the brachial artery between the beginning and end of each treatment period (Montelukast and placebo), expressed as absolute value (FMD unit is %) and measured in a standardized manner.</measure>
    <time_frame>before and after 3 months treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentrations of urinary LTE4 at the beginning and end of each treatment period</measure>
    <time_frame>before and after 3 months the two periods of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24h ambulatory blood pressure (systolic and diastolic) measurement</measure>
    <time_frame>before and after 3 months of the two periods of treatment, and 15 days after the last period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polysomnography at inclusion and at the end of each treatment period</measure>
    <time_frame>inclusion and at the end of the two periods of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of Montelukast measured by HPLC-MS at the end of the Montelukast treatment period</measure>
    <time_frame>at the end of Montelukast treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Collection of adverse events</measure>
    <time_frame>from inclusion to 15 days after the last period of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Cardiovascular Events occurence (myocardial infarction, Stroke, Cardiovascular Death) between the two periods</measure>
    <time_frame>from inclusion to 15 days after the last period of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of plasma CRPus at baseline and at the beginning and end of each treatment period</measure>
    <time_frame>before and after 3 months the two periods of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Sleep Apnea, Obstructive</condition>
  <arm_group>
    <arm_group_label>Montelukast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug :Montelukast, capsule, 10mg, one per day in the evening, one hour before or 2 hours post meal, length of treatment 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: Mannitol, capsule, 350mg, one per day in the evening, one hour before or 2 hours post meal, length of treatment 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montelukast 10mg</intervention_name>
    <description>The capsules will be presented in box of 95 capsules packaged in unit blister</description>
    <arm_group_label>Montelukast</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Mannitol 350mg The capsules will be presented in box of 95 capsules packaged in unit blister</description>
    <arm_group_label>Montelukast</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  With mild to moderate obstructive sleep apnea syndrome (apnea / hypopnea index&gt; 15 and&#xD;
             &lt;30 events per hour)&#xD;
&#xD;
          -  Little symptomatic (Epworth sleepiness score &lt;10)&#xD;
&#xD;
          -  Polysomnography within 3 months prior to inclusion&#xD;
&#xD;
          -  With a history of myocardial infarction or stroke&#xD;
&#xD;
          -  Affiliation to Social Security or beneficiary of such a scheme&#xD;
&#xD;
          -  Signed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  OSAS support by PPC&#xD;
&#xD;
          -  Cancer&#xD;
&#xD;
          -  Chronic inflammatory disease&#xD;
&#xD;
          -  Asthma previously treated with Montelukast&#xD;
&#xD;
          -  Chronic infectious disease&#xD;
&#xD;
          -  Epworth sleepiness scale ≥10&#xD;
&#xD;
          -  Contraindication to Montelukast: Hypersensitivity to the active substance or to the&#xD;
             excipients&#xD;
&#xD;
          -  Contraindications to trinitrin: hypersensitivity to nitrates, state of shock, severe&#xD;
             hypotension, association with sildenafil, obstructive cardiomyopathy, inferior right&#xD;
             sided myocardial infarction with right ventricular extension, acute, except in case of&#xD;
             signs left ventricular failure, intracranial hypertension, breastfeeding&#xD;
&#xD;
          -  Treatment with phenobarbital, phenytoin, rifampicin: risk of montelukast metabolism&#xD;
             increase and thus decrease of its effectiveness&#xD;
&#xD;
          -  Persons referred in Articles L1121-5 to L1121-8 of the CSP (pregnant woman,&#xD;
             parturient, nursing mothers, person deprived of liberty by judicial or administrative&#xD;
             decision, person subject to a measure of legal protection, can not be included in&#xD;
             clinical trials)&#xD;
&#xD;
          -  Subject in exclusion period of another study&#xD;
&#xD;
          -  Subject can not be contacted in case of emergency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Métropole Savoie Hospital</name>
      <address>
        <city>Chambéry</city>
        <zip>73000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Annecy Genevois Hospital</name>
      <address>
        <city>Metz-Tessy</city>
        <zip>74370</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Saint-Étienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Ingelsson E, Yin L, Bäck M. Nationwide cohort study of the leukotriene receptor antagonist montelukast and incident or recurrent cardiovascular disease. J Allergy Clin Immunol. 2012 Mar;129(3):702-707.e2. doi: 10.1016/j.jaci.2011.11.052. Epub 2012 Jan 12.</citation>
    <PMID>22244598</PMID>
  </reference>
  <reference>
    <citation>Goldbart AD, Greenberg-Dotan S, Tal A. Montelukast for children with obstructive sleep apnea: a double-blind, placebo-controlled study. Pediatrics. 2012 Sep;130(3):e575-80. doi: 10.1542/peds.2012-0310. Epub 2012 Aug 6.</citation>
    <PMID>22869829</PMID>
  </reference>
  <reference>
    <citation>Cereza G, Garcia Doladé N, Laporte JR. Nightmares induced by montelukast in children and adults. Eur Respir J. 2012 Dec;40(6):1574-5. doi: 10.1183/09031936.00092812.</citation>
    <PMID>23204025</PMID>
  </reference>
  <reference>
    <citation>Marchand M-S, Jonville-Béra A-P, Autret-Leca E. [Psychiatric disorders associated with montelukast: data from the National Pharmacovigilance Database]. Arch pédiatrie organe Off la Sociéte Fr pédiatrie [Internet]. 2013 [cited 2016 Jun 14];20:269-73. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23375423</citation>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>May 16, 2018</study_first_submitted>
  <study_first_submitted_qc>June 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2018</study_first_posted>
  <last_update_submitted>February 15, 2021</last_update_submitted>
  <last_update_submitted_qc>February 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Montelukast</keyword>
  <keyword>leukotriene pathway</keyword>
  <keyword>endothelial function</keyword>
  <keyword>flux-mediated dilation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

